nodes	percent_of_prediction	percent_of_DWPC	metapath
Alendronate—PTPRE—vein—ovarian cancer	0.11	0.234	CbGeAlD
Alendronate—PTPRE—decidua—ovarian cancer	0.016	0.0342	CbGeAlD
Alendronate—PTPN4—uterine cervix—ovarian cancer	0.016	0.0341	CbGeAlD
Alendronate—PTPRS—ECM proteoglycans—ITGA8—ovarian cancer	0.0141	0.121	CbGpPWpGaD
Alendronate—PTPN4—uterus—ovarian cancer	0.0133	0.0284	CbGeAlD
Alendronate—PTPRE—female reproductive system—ovarian cancer	0.0126	0.0269	CbGeAlD
Alendronate—PTPN4—female reproductive system—ovarian cancer	0.012	0.0255	CbGeAlD
Alendronate—PTPRE—bone marrow—ovarian cancer	0.0119	0.0254	CbGeAlD
Alendronate—PTPRE—female gonad—ovarian cancer	0.0114	0.0244	CbGeAlD
Alendronate—PTPRE—vagina—ovarian cancer	0.0114	0.0243	CbGeAlD
Alendronate—PTPN4—bone marrow—ovarian cancer	0.0113	0.0241	CbGeAlD
Alendronate—PTPN4—female gonad—ovarian cancer	0.0109	0.0232	CbGeAlD
Alendronate—PTPN4—vagina—ovarian cancer	0.0108	0.0231	CbGeAlD
Alendronate—PTPRS—female reproductive system—ovarian cancer	0.0103	0.0219	CbGeAlD
Alendronate—PTPRE—testis—ovarian cancer	0.0102	0.0217	CbGeAlD
Alendronate—ATP6V1A—myometrium—ovarian cancer	0.0101	0.0217	CbGeAlD
Alendronate—ATP6V1A—embryo—ovarian cancer	0.00976	0.0208	CbGeAlD
Alendronate—PTPRS—bone marrow—ovarian cancer	0.00968	0.0207	CbGeAlD
Alendronate—PTPN4—testis—ovarian cancer	0.00966	0.0206	CbGeAlD
Alendronate—PTPRS—female gonad—ovarian cancer	0.00933	0.0199	CbGeAlD
Alendronate—PTPRS—ECM proteoglycans—SPARC—ovarian cancer	0.00908	0.0779	CbGpPWpGaD
Alendronate—PTPRE—IL6-mediated signaling events—IL6ST—ovarian cancer	0.00903	0.0775	CbGpPWpGaD
Alendronate—PTPRS—testis—ovarian cancer	0.00828	0.0177	CbGeAlD
Alendronate—ATP6V1A—uterine cervix—ovarian cancer	0.00789	0.0169	CbGeAlD
Alendronate—FDPS—myometrium—ovarian cancer	0.00764	0.0163	CbGeAlD
Alendronate—ATP6V1A—decidua—ovarian cancer	0.00752	0.0161	CbGeAlD
Alendronate—PTPRE—lymph node—ovarian cancer	0.00736	0.0157	CbGeAlD
Alendronate—ATP6V1A—endometrium—ovarian cancer	0.00714	0.0152	CbGeAlD
Alendronate—PTPN4—lymph node—ovarian cancer	0.007	0.0149	CbGeAlD
Alendronate—ATP6V1A—gonad—ovarian cancer	0.00662	0.0141	CbGeAlD
Alendronate—ATP6V1A—uterus—ovarian cancer	0.00658	0.014	CbGeAlD
Alendronate—PTPRS—lymph node—ovarian cancer	0.006	0.0128	CbGeAlD
Alendronate—FDPS—uterine cervix—ovarian cancer	0.00595	0.0127	CbGeAlD
Alendronate—ATP6V1A—female reproductive system—ovarian cancer	0.00591	0.0126	CbGeAlD
Alendronate—FDPS—decidua—ovarian cancer	0.00567	0.0121	CbGeAlD
Alendronate—ATP6V1A—bone marrow—ovarian cancer	0.00558	0.0119	CbGeAlD
Alendronate—ATP6V1A—female gonad—ovarian cancer	0.00538	0.0115	CbGeAlD
Alendronate—FDPS—endometrium—ovarian cancer	0.00538	0.0115	CbGeAlD
Alendronate—ATP6V1A—vagina—ovarian cancer	0.00535	0.0114	CbGeAlD
Alendronate—PTPRE—IL6-mediated signaling events—STAT3—ovarian cancer	0.00514	0.0441	CbGpPWpGaD
Alendronate—FDPS—gonad—ovarian cancer	0.00499	0.0106	CbGeAlD
Alendronate—FDPS—uterus—ovarian cancer	0.00496	0.0106	CbGeAlD
Alendronate—PTPRE—IL6-mediated signaling events—MYC—ovarian cancer	0.00478	0.041	CbGpPWpGaD
Alendronate—ATP6V1A—testis—ovarian cancer	0.00477	0.0102	CbGeAlD
Alendronate—FDPS—female reproductive system—ovarian cancer	0.00446	0.00951	CbGeAlD
Alendronate—ATP6V1A—Signaling by Insulin receptor—DOK1—ovarian cancer	0.00425	0.0365	CbGpPWpGaD
Alendronate—FDPS—bone marrow—ovarian cancer	0.00421	0.00898	CbGeAlD
Alendronate—FDPS—Activation of gene expression by SREBF (SREBP)—FASN—ovarian cancer	0.0041	0.0351	CbGpPWpGaD
Alendronate—FDPS—female gonad—ovarian cancer	0.00405	0.00865	CbGeAlD
Alendronate—PTPRE—IL6-mediated signaling events—PIK3CA—ovarian cancer	0.00405	0.0348	CbGpPWpGaD
Alendronate—FDPS—vagina—ovarian cancer	0.00403	0.0086	CbGeAlD
Alendronate—PTPRS—Extracellular matrix organization—ITGA8—ovarian cancer	0.00402	0.0345	CbGpPWpGaD
Alendronate—FDPS—testis—ovarian cancer	0.0036	0.00768	CbGeAlD
Alendronate—PTPRE—IL6-mediated signaling events—IL6—ovarian cancer	0.00359	0.0308	CbGpPWpGaD
Alendronate—ATP6V1A—lymph node—ovarian cancer	0.00346	0.00739	CbGeAlD
Alendronate—PTPRE—IL6-mediated signaling events—AKT1—ovarian cancer	0.00331	0.0284	CbGpPWpGaD
Alendronate—FDPS—Regulation of cholesterol biosynthesis by SREBP (SREBF)—FASN—ovarian cancer	0.00327	0.028	CbGpPWpGaD
Alendronate—FDPS—SREBP signalling—FASN—ovarian cancer	0.00265	0.0227	CbGpPWpGaD
Alendronate—FDPS—lymph node—ovarian cancer	0.00261	0.00556	CbGeAlD
Alendronate—PTPRS—Extracellular matrix organization—SPARC—ovarian cancer	0.00259	0.0222	CbGpPWpGaD
Alendronate—Ulcer—Epirubicin—ovarian cancer	0.00131	0.00315	CcSEcCtD
Alendronate—Infection—Melphalan—ovarian cancer	0.0013	0.00314	CcSEcCtD
Alendronate—Ill-defined disorder—Vinorelbine—ovarian cancer	0.0013	0.00314	CcSEcCtD
Alendronate—Anaemia—Vinorelbine—ovarian cancer	0.0013	0.00313	CcSEcCtD
Alendronate—Pain—Chlorambucil—ovarian cancer	0.00129	0.0031	CcSEcCtD
Alendronate—Angioedema—Vinorelbine—ovarian cancer	0.00128	0.0031	CcSEcCtD
Alendronate—Malaise—Vinorelbine—ovarian cancer	0.00127	0.00305	CcSEcCtD
Alendronate—Vertigo—Vinorelbine—ovarian cancer	0.00126	0.00304	CcSEcCtD
Alendronate—Musculoskeletal pain—Epirubicin—ovarian cancer	0.00125	0.00302	CcSEcCtD
Alendronate—Hypocalcaemia—Doxorubicin—ovarian cancer	0.00125	0.00301	CcSEcCtD
Alendronate—Feeling abnormal—Chlorambucil—ovarian cancer	0.00124	0.00299	CcSEcCtD
Alendronate—Photosensitivity reaction—Paclitaxel—ovarian cancer	0.00124	0.00298	CcSEcCtD
Alendronate—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.00123	0.00297	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—IL6ST—ovarian cancer	0.00123	0.0105	CbGpPWpGaD
Alendronate—Musculoskeletal discomfort—Topotecan—ovarian cancer	0.00122	0.00294	CcSEcCtD
Alendronate—Dry skin—Docetaxel—ovarian cancer	0.00122	0.00294	CcSEcCtD
Alendronate—Ulcer—Doxorubicin—ovarian cancer	0.00121	0.00291	CcSEcCtD
Alendronate—Melaena—Epirubicin—ovarian cancer	0.00121	0.00291	CcSEcCtD
Alendronate—Influenza like illness—Epirubicin—ovarian cancer	0.0012	0.00289	CcSEcCtD
Alendronate—Stevens-Johnson syndrome—Paclitaxel—ovarian cancer	0.0012	0.00289	CcSEcCtD
Alendronate—Cramp muscle—Docetaxel—ovarian cancer	0.0012	0.00289	CcSEcCtD
Alendronate—Toxic epidermal necrolysis—Docetaxel—ovarian cancer	0.0012	0.00289	CcSEcCtD
Alendronate—Urticaria—Chlorambucil—ovarian cancer	0.0012	0.00288	CcSEcCtD
Alendronate—Chest pain—Vinorelbine—ovarian cancer	0.0012	0.00288	CcSEcCtD
Alendronate—Myalgia—Vinorelbine—ovarian cancer	0.0012	0.00288	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.0012	0.00288	CcSEcCtD
Alendronate—Abdominal pain—Chlorambucil—ovarian cancer	0.00119	0.00287	CcSEcCtD
Alendronate—Body temperature increased—Chlorambucil—ovarian cancer	0.00119	0.00287	CcSEcCtD
Alendronate—Discomfort—Vinorelbine—ovarian cancer	0.00118	0.00285	CcSEcCtD
Alendronate—Dyspepsia—Topotecan—ovarian cancer	0.00118	0.00284	CcSEcCtD
Alendronate—Stomatitis—Paclitaxel—ovarian cancer	0.00118	0.00284	CcSEcCtD
Alendronate—Musculoskeletal pain—Doxorubicin—ovarian cancer	0.00116	0.00279	CcSEcCtD
Alendronate—ATP6V1A—Disease—HSD17B6—ovarian cancer	0.00116	0.00992	CbGpPWpGaD
Alendronate—Dyspepsia—Melphalan—ovarian cancer	0.00116	0.00279	CcSEcCtD
Alendronate—PTPRS—Extracellular matrix organization—CDH1—ovarian cancer	0.00115	0.00989	CbGpPWpGaD
Alendronate—Dysphagia—Docetaxel—ovarian cancer	0.00115	0.00277	CcSEcCtD
Alendronate—Constipation—Topotecan—ovarian cancer	0.00115	0.00276	CcSEcCtD
Alendronate—Pain—Topotecan—ovarian cancer	0.00115	0.00276	CcSEcCtD
Alendronate—Infection—Vinorelbine—ovarian cancer	0.00114	0.00275	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—AQP3—ovarian cancer	0.00113	0.00971	CbGpPWpGaD
Alendronate—Oesophagitis—Epirubicin—ovarian cancer	0.00113	0.00272	CcSEcCtD
Alendronate—Pain—Melphalan—ovarian cancer	0.00112	0.00271	CcSEcCtD
Alendronate—Melaena—Doxorubicin—ovarian cancer	0.00112	0.00269	CcSEcCtD
Alendronate—Influenza like illness—Doxorubicin—ovarian cancer	0.00111	0.00268	CcSEcCtD
Alendronate—PTPRS—Extracellular matrix organization—MMP2—ovarian cancer	0.00111	0.00952	CbGpPWpGaD
Alendronate—Hypersensitivity—Chlorambucil—ovarian cancer	0.00111	0.00267	CcSEcCtD
Alendronate—Feeling abnormal—Topotecan—ovarian cancer	0.0011	0.00266	CcSEcCtD
Alendronate—FDPS—SREBP signalling—MTOR—ovarian cancer	0.0011	0.00941	CbGpPWpGaD
Alendronate—Gastrointestinal pain—Topotecan—ovarian cancer	0.0011	0.00264	CcSEcCtD
Alendronate—Haemoglobin—Paclitaxel—ovarian cancer	0.00109	0.00263	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—ATP7B—ovarian cancer	0.00109	0.00931	CbGpPWpGaD
Alendronate—Haemorrhage—Paclitaxel—ovarian cancer	0.00109	0.00262	CcSEcCtD
Alendronate—Asthenia—Chlorambucil—ovarian cancer	0.00108	0.0026	CcSEcCtD
Alendronate—Oedema peripheral—Paclitaxel—ovarian cancer	0.00107	0.00258	CcSEcCtD
Alendronate—Pruritus—Chlorambucil—ovarian cancer	0.00107	0.00257	CcSEcCtD
Alendronate—Urticaria—Topotecan—ovarian cancer	0.00107	0.00257	CcSEcCtD
Alendronate—Abdominal pain—Topotecan—ovarian cancer	0.00106	0.00255	CcSEcCtD
Alendronate—Body temperature increased—Topotecan—ovarian cancer	0.00106	0.00255	CcSEcCtD
Alendronate—Oesophagitis—Doxorubicin—ovarian cancer	0.00105	0.00252	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.00105	0.00252	CcSEcCtD
Alendronate—Urticaria—Melphalan—ovarian cancer	0.00104	0.00251	CcSEcCtD
Alendronate—Diarrhoea—Chlorambucil—ovarian cancer	0.00103	0.00248	CcSEcCtD
Alendronate—Erythema multiforme—Paclitaxel—ovarian cancer	0.00103	0.00247	CcSEcCtD
Alendronate—Photosensitivity—Epirubicin—ovarian cancer	0.00102	0.00246	CcSEcCtD
Alendronate—Stevens-Johnson syndrome—Docetaxel—ovarian cancer	0.00102	0.00245	CcSEcCtD
Alendronate—Stomatitis—Docetaxel—ovarian cancer	0.000999	0.00241	CcSEcCtD
Alendronate—Hypersensitivity—Topotecan—ovarian cancer	0.000988	0.00238	CcSEcCtD
Alendronate—Constipation—Vinorelbine—ovarian cancer	0.000981	0.00236	CcSEcCtD
Alendronate—Pain—Vinorelbine—ovarian cancer	0.000981	0.00236	CcSEcCtD
Alendronate—Hypersensitivity—Melphalan—ovarian cancer	0.000967	0.00233	CcSEcCtD
Alendronate—Asthenia—Topotecan—ovarian cancer	0.000962	0.00232	CcSEcCtD
Alendronate—Alopecia—Paclitaxel—ovarian cancer	0.00096	0.00231	CcSEcCtD
Alendronate—Vomiting—Chlorambucil—ovarian cancer	0.000958	0.00231	CcSEcCtD
Alendronate—Pruritus—Topotecan—ovarian cancer	0.000949	0.00229	CcSEcCtD
Alendronate—Photosensitivity—Doxorubicin—ovarian cancer	0.000946	0.00228	CcSEcCtD
Alendronate—Erythema—Paclitaxel—ovarian cancer	0.000945	0.00228	CcSEcCtD
Alendronate—Feeling abnormal—Vinorelbine—ovarian cancer	0.000945	0.00228	CcSEcCtD
Alendronate—Asthenia—Melphalan—ovarian cancer	0.000942	0.00227	CcSEcCtD
Alendronate—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000938	0.00226	CcSEcCtD
Alendronate—Flatulence—Paclitaxel—ovarian cancer	0.000932	0.00225	CcSEcCtD
Alendronate—Pruritus—Melphalan—ovarian cancer	0.000929	0.00224	CcSEcCtD
Alendronate—Dysgeusia—Paclitaxel—ovarian cancer	0.000926	0.00223	CcSEcCtD
Alendronate—Haemoglobin—Docetaxel—ovarian cancer	0.000925	0.00223	CcSEcCtD
Alendronate—ATP6V1A—Disease—CHMP4C—ovarian cancer	0.000924	0.00793	CbGpPWpGaD
Alendronate—Haemorrhage—Docetaxel—ovarian cancer	0.00092	0.00222	CcSEcCtD
Alendronate—Diarrhoea—Topotecan—ovarian cancer	0.000917	0.00221	CcSEcCtD
Alendronate—Urticaria—Vinorelbine—ovarian cancer	0.000911	0.0022	CcSEcCtD
Alendronate—Muscle spasms—Paclitaxel—ovarian cancer	0.000909	0.00219	CcSEcCtD
Alendronate—Abdominal pain—Vinorelbine—ovarian cancer	0.000907	0.00219	CcSEcCtD
Alendronate—Body temperature increased—Vinorelbine—ovarian cancer	0.000907	0.00219	CcSEcCtD
Alendronate—Oedema peripheral—Docetaxel—ovarian cancer	0.000907	0.00219	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—MTOR—ovarian cancer	0.000905	0.00777	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling by Insulin receptor—PIK3CB—ovarian cancer	0.000905	0.00777	CbGpPWpGaD
Alendronate—Diarrhoea—Melphalan—ovarian cancer	0.000898	0.00217	CcSEcCtD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000895	0.00768	CbGpPWpGaD
Alendronate—Nausea—Chlorambucil—ovarian cancer	0.000895	0.00216	CcSEcCtD
Alendronate—Dizziness—Topotecan—ovarian cancer	0.000887	0.00214	CcSEcCtD
Alendronate—PTPRS—Extracellular matrix organization—CASP3—ovarian cancer	0.000883	0.00757	CbGpPWpGaD
Alendronate—Ill-defined disorder—Paclitaxel—ovarian cancer	0.000877	0.00211	CcSEcCtD
Alendronate—Anaemia—Paclitaxel—ovarian cancer	0.000874	0.00211	CcSEcCtD
Alendronate—Erythema multiforme—Docetaxel—ovarian cancer	0.00087	0.0021	CcSEcCtD
Alendronate—Angioedema—Paclitaxel—ovarian cancer	0.000864	0.00208	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—TUBB3—ovarian cancer	0.000858	0.00736	CbGpPWpGaD
Alendronate—Vomiting—Topotecan—ovarian cancer	0.000853	0.00205	CcSEcCtD
Alendronate—Malaise—Paclitaxel—ovarian cancer	0.000852	0.00205	CcSEcCtD
Alendronate—Vertigo—Paclitaxel—ovarian cancer	0.000849	0.00205	CcSEcCtD
Alendronate—Rash—Topotecan—ovarian cancer	0.000845	0.00204	CcSEcCtD
Alendronate—Hypersensitivity—Vinorelbine—ovarian cancer	0.000845	0.00204	CcSEcCtD
Alendronate—Dermatitis—Topotecan—ovarian cancer	0.000845	0.00204	CcSEcCtD
Alendronate—Headache—Topotecan—ovarian cancer	0.00084	0.00202	CcSEcCtD
Alendronate—Vomiting—Melphalan—ovarian cancer	0.000835	0.00201	CcSEcCtD
Alendronate—PTPRS—Extracellular matrix organization—MMP9—ovarian cancer	0.000835	0.00716	CbGpPWpGaD
Alendronate—Rash—Melphalan—ovarian cancer	0.000828	0.002	CcSEcCtD
Alendronate—Dermatitis—Melphalan—ovarian cancer	0.000827	0.00199	CcSEcCtD
Alendronate—Asthenia—Vinorelbine—ovarian cancer	0.000823	0.00198	CcSEcCtD
Alendronate—Dry skin—Epirubicin—ovarian cancer	0.000823	0.00198	CcSEcCtD
Alendronate—Alopecia—Docetaxel—ovarian cancer	0.000813	0.00196	CcSEcCtD
Alendronate—Pruritus—Vinorelbine—ovarian cancer	0.000812	0.00196	CcSEcCtD
Alendronate—ATP6V1A—Signaling Pathways—HSD17B6—ovarian cancer	0.00081	0.00694	CbGpPWpGaD
Alendronate—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.000808	0.00195	CcSEcCtD
Alendronate—Chest pain—Paclitaxel—ovarian cancer	0.000805	0.00194	CcSEcCtD
Alendronate—Myalgia—Paclitaxel—ovarian cancer	0.000805	0.00194	CcSEcCtD
Alendronate—ATP6V1A—Disease—BCL9—ovarian cancer	0.000801	0.00687	CbGpPWpGaD
Alendronate—Erythema—Docetaxel—ovarian cancer	0.000801	0.00193	CcSEcCtD
Alendronate—Nausea—Topotecan—ovarian cancer	0.000796	0.00192	CcSEcCtD
Alendronate—Discomfort—Paclitaxel—ovarian cancer	0.000795	0.00192	CcSEcCtD
Alendronate—Gastritis—Epirubicin—ovarian cancer	0.000794	0.00191	CcSEcCtD
Alendronate—Diarrhoea—Vinorelbine—ovarian cancer	0.000785	0.00189	CcSEcCtD
Alendronate—Dysgeusia—Docetaxel—ovarian cancer	0.000785	0.00189	CcSEcCtD
Alendronate—Abdominal distension—Epirubicin—ovarian cancer	0.000781	0.00188	CcSEcCtD
Alendronate—Nausea—Melphalan—ovarian cancer	0.00078	0.00188	CcSEcCtD
Alendronate—Dysphagia—Epirubicin—ovarian cancer	0.000776	0.00187	CcSEcCtD
Alendronate—Asthma—Epirubicin—ovarian cancer	0.000776	0.00187	CcSEcCtD
Alendronate—Muscle spasms—Docetaxel—ovarian cancer	0.00077	0.00186	CcSEcCtD
Alendronate—Infection—Paclitaxel—ovarian cancer	0.000766	0.00185	CcSEcCtD
Alendronate—Dry skin—Doxorubicin—ovarian cancer	0.000761	0.00183	CcSEcCtD
Alendronate—Dizziness—Vinorelbine—ovarian cancer	0.000759	0.00183	CcSEcCtD
Alendronate—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.000748	0.0018	CcSEcCtD
Alendronate—Anaemia—Docetaxel—ovarian cancer	0.000741	0.00178	CcSEcCtD
Alendronate—Gastritis—Doxorubicin—ovarian cancer	0.000735	0.00177	CcSEcCtD
Alendronate—Vomiting—Vinorelbine—ovarian cancer	0.000729	0.00176	CcSEcCtD
Alendronate—Rash—Vinorelbine—ovarian cancer	0.000723	0.00174	CcSEcCtD
Alendronate—Dermatitis—Vinorelbine—ovarian cancer	0.000723	0.00174	CcSEcCtD
Alendronate—Abdominal distension—Doxorubicin—ovarian cancer	0.000723	0.00174	CcSEcCtD
Alendronate—Headache—Vinorelbine—ovarian cancer	0.000719	0.00173	CcSEcCtD
Alendronate—Dysphagia—Doxorubicin—ovarian cancer	0.000718	0.00173	CcSEcCtD
Alendronate—Asthma—Doxorubicin—ovarian cancer	0.000718	0.00173	CcSEcCtD
Alendronate—Photosensitivity reaction—Epirubicin—ovarian cancer	0.000708	0.00171	CcSEcCtD
Alendronate—FDPS—Metabolism—NME2—ovarian cancer	0.000708	0.00607	CbGpPWpGaD
Alendronate—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000703	0.00169	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—NRAS—ovarian cancer	0.000698	0.00599	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—DLC1—ovarian cancer	0.000688	0.0059	CbGpPWpGaD
Alendronate—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000686	0.00165	CcSEcCtD
Alendronate—Chest pain—Docetaxel—ovarian cancer	0.000682	0.00164	CcSEcCtD
Alendronate—Myalgia—Docetaxel—ovarian cancer	0.000682	0.00164	CcSEcCtD
Alendronate—Nausea—Vinorelbine—ovarian cancer	0.000681	0.00164	CcSEcCtD
Alendronate—Dyspepsia—Paclitaxel—ovarian cancer	0.000679	0.00164	CcSEcCtD
Alendronate—Stomatitis—Epirubicin—ovarian cancer	0.000674	0.00162	CcSEcCtD
Alendronate—FDPS—SREBP signalling—PIK3CA—ovarian cancer	0.000669	0.00573	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling by Insulin receptor—MAPK3—ovarian cancer	0.000669	0.00573	CbGpPWpGaD
Alendronate—Constipation—Paclitaxel—ovarian cancer	0.00066	0.00159	CcSEcCtD
Alendronate—Pain—Paclitaxel—ovarian cancer	0.00066	0.00159	CcSEcCtD
Alendronate—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000655	0.00158	CcSEcCtD
Alendronate—Infection—Docetaxel—ovarian cancer	0.00065	0.00157	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—MAPK1—ovarian cancer	0.000636	0.00546	CbGpPWpGaD
Alendronate—Feeling abnormal—Paclitaxel—ovarian cancer	0.000636	0.00153	CcSEcCtD
Alendronate—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000634	0.00153	CcSEcCtD
Alendronate—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000631	0.00152	CcSEcCtD
Alendronate—Haemoglobin—Epirubicin—ovarian cancer	0.000624	0.0015	CcSEcCtD
Alendronate—Stomatitis—Doxorubicin—ovarian cancer	0.000624	0.0015	CcSEcCtD
Alendronate—Haemorrhage—Epirubicin—ovarian cancer	0.000621	0.0015	CcSEcCtD
Alendronate—Urticaria—Paclitaxel—ovarian cancer	0.000613	0.00148	CcSEcCtD
Alendronate—Oedema peripheral—Epirubicin—ovarian cancer	0.000612	0.00147	CcSEcCtD
Alendronate—Abdominal pain—Paclitaxel—ovarian cancer	0.00061	0.00147	CcSEcCtD
Alendronate—Body temperature increased—Paclitaxel—ovarian cancer	0.00061	0.00147	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—KRAS—ovarian cancer	0.000601	0.00515	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	0.000601	0.00515	CbGpPWpGaD
Alendronate—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000596	0.00144	CcSEcCtD
Alendronate—ATP6V1A—Disease—PPP1CC—ovarian cancer	0.000596	0.00511	CbGpPWpGaD
Alendronate—Erythema multiforme—Epirubicin—ovarian cancer	0.000587	0.00141	CcSEcCtD
Alendronate—Haemoglobin—Doxorubicin—ovarian cancer	0.000577	0.00139	CcSEcCtD
Alendronate—Dyspepsia—Docetaxel—ovarian cancer	0.000576	0.00139	CcSEcCtD
Alendronate—Haemorrhage—Doxorubicin—ovarian cancer	0.000574	0.00138	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	0.000573	0.00491	CbGpPWpGaD
Alendronate—Hypersensitivity—Paclitaxel—ovarian cancer	0.000568	0.00137	CcSEcCtD
Alendronate—Oedema peripheral—Doxorubicin—ovarian cancer	0.000566	0.00136	CcSEcCtD
Alendronate—ATP6V1A—Signaling Pathways—BCL9—ovarian cancer	0.000561	0.00481	CbGpPWpGaD
Alendronate—Constipation—Docetaxel—ovarian cancer	0.000559	0.00135	CcSEcCtD
Alendronate—Pain—Docetaxel—ovarian cancer	0.000559	0.00135	CcSEcCtD
Alendronate—Asthenia—Paclitaxel—ovarian cancer	0.000554	0.00133	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	0.000553	0.00474	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling by Insulin receptor—PIK3CA—ovarian cancer	0.000552	0.00473	CbGpPWpGaD
Alendronate—Alopecia—Epirubicin—ovarian cancer	0.000549	0.00132	CcSEcCtD
Alendronate—FDPS—SREBP signalling—AKT1—ovarian cancer	0.000546	0.00468	CbGpPWpGaD
Alendronate—Pruritus—Paclitaxel—ovarian cancer	0.000546	0.00132	CcSEcCtD
Alendronate—Erythema multiforme—Doxorubicin—ovarian cancer	0.000543	0.00131	CcSEcCtD
Alendronate—Erythema—Epirubicin—ovarian cancer	0.00054	0.0013	CcSEcCtD
Alendronate—Feeling abnormal—Docetaxel—ovarian cancer	0.000539	0.0013	CcSEcCtD
Alendronate—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000535	0.00129	CcSEcCtD
Alendronate—Flatulence—Epirubicin—ovarian cancer	0.000533	0.00128	CcSEcCtD
Alendronate—Dysgeusia—Epirubicin—ovarian cancer	0.000529	0.00128	CcSEcCtD
Alendronate—Diarrhoea—Paclitaxel—ovarian cancer	0.000528	0.00127	CcSEcCtD
Alendronate—Muscle spasms—Epirubicin—ovarian cancer	0.00052	0.00125	CcSEcCtD
Alendronate—Body temperature increased—Docetaxel—ovarian cancer	0.000517	0.00125	CcSEcCtD
Alendronate—Abdominal pain—Docetaxel—ovarian cancer	0.000517	0.00125	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—HRAS—ovarian cancer	0.000511	0.00438	CbGpPWpGaD
Alendronate—Dizziness—Paclitaxel—ovarian cancer	0.00051	0.00123	CcSEcCtD
Alendronate—Alopecia—Doxorubicin—ovarian cancer	0.000508	0.00122	CcSEcCtD
Alendronate—Ill-defined disorder—Epirubicin—ovarian cancer	0.000501	0.00121	CcSEcCtD
Alendronate—Erythema—Doxorubicin—ovarian cancer	0.0005	0.00121	CcSEcCtD
Alendronate—Anaemia—Epirubicin—ovarian cancer	0.0005	0.0012	CcSEcCtD
Alendronate—Flatulence—Doxorubicin—ovarian cancer	0.000493	0.00119	CcSEcCtD
Alendronate—Vomiting—Paclitaxel—ovarian cancer	0.000491	0.00118	CcSEcCtD
Alendronate—Dysgeusia—Doxorubicin—ovarian cancer	0.00049	0.00118	CcSEcCtD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	0.00049	0.0042	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling by Insulin receptor—IL6—ovarian cancer	0.000489	0.00419	CbGpPWpGaD
Alendronate—Malaise—Epirubicin—ovarian cancer	0.000487	0.00117	CcSEcCtD
Alendronate—Rash—Paclitaxel—ovarian cancer	0.000486	0.00117	CcSEcCtD
Alendronate—Dermatitis—Paclitaxel—ovarian cancer	0.000486	0.00117	CcSEcCtD
Alendronate—Vertigo—Epirubicin—ovarian cancer	0.000486	0.00117	CcSEcCtD
Alendronate—Headache—Paclitaxel—ovarian cancer	0.000483	0.00116	CcSEcCtD
Alendronate—Hypersensitivity—Docetaxel—ovarian cancer	0.000482	0.00116	CcSEcCtD
Alendronate—Muscle spasms—Doxorubicin—ovarian cancer	0.000481	0.00116	CcSEcCtD
Alendronate—Asthenia—Docetaxel—ovarian cancer	0.000469	0.00113	CcSEcCtD
Alendronate—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000464	0.00112	CcSEcCtD
Alendronate—Pruritus—Docetaxel—ovarian cancer	0.000463	0.00112	CcSEcCtD
Alendronate—Anaemia—Doxorubicin—ovarian cancer	0.000462	0.00111	CcSEcCtD
Alendronate—Myalgia—Epirubicin—ovarian cancer	0.00046	0.00111	CcSEcCtD
Alendronate—Chest pain—Epirubicin—ovarian cancer	0.00046	0.00111	CcSEcCtD
Alendronate—Nausea—Paclitaxel—ovarian cancer	0.000458	0.0011	CcSEcCtD
Alendronate—FDPS—Metabolism—CYTB—ovarian cancer	0.000456	0.00391	CbGpPWpGaD
Alendronate—Discomfort—Epirubicin—ovarian cancer	0.000455	0.0011	CcSEcCtD
Alendronate—ATP6V1A—Disease—HDAC6—ovarian cancer	0.000451	0.00387	CbGpPWpGaD
Alendronate—Malaise—Doxorubicin—ovarian cancer	0.000451	0.00109	CcSEcCtD
Alendronate—Vertigo—Doxorubicin—ovarian cancer	0.000449	0.00108	CcSEcCtD
Alendronate—Diarrhoea—Docetaxel—ovarian cancer	0.000447	0.00108	CcSEcCtD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	0.000446	0.00382	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—DOK1—ovarian cancer	0.000444	0.0038	CbGpPWpGaD
Alendronate—Infection—Epirubicin—ovarian cancer	0.000438	0.00106	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—ABCB1—ovarian cancer	0.000437	0.00375	CbGpPWpGaD
Alendronate—Dizziness—Docetaxel—ovarian cancer	0.000432	0.00104	CcSEcCtD
Alendronate—Myalgia—Doxorubicin—ovarian cancer	0.000426	0.00103	CcSEcCtD
Alendronate—Chest pain—Doxorubicin—ovarian cancer	0.000426	0.00103	CcSEcCtD
Alendronate—Discomfort—Doxorubicin—ovarian cancer	0.000421	0.00101	CcSEcCtD
Alendronate—ATP6V1A—Signaling Pathways—PPP1CC—ovarian cancer	0.000417	0.00358	CbGpPWpGaD
Alendronate—Vomiting—Docetaxel—ovarian cancer	0.000416	0.001	CcSEcCtD
Alendronate—Rash—Docetaxel—ovarian cancer	0.000412	0.000994	CcSEcCtD
Alendronate—Dermatitis—Docetaxel—ovarian cancer	0.000412	0.000993	CcSEcCtD
Alendronate—Headache—Docetaxel—ovarian cancer	0.00041	0.000987	CcSEcCtD
Alendronate—Infection—Doxorubicin—ovarian cancer	0.000405	0.000977	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000402	0.000969	CcSEcCtD
Alendronate—FDPS—Metabolism—PPP1CC—ovarian cancer	0.000399	0.00342	CbGpPWpGaD
Alendronate—FDPS—Metabolism—BRIP1—ovarian cancer	0.000399	0.00342	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—XIAP—ovarian cancer	0.000391	0.00336	CbGpPWpGaD
Alendronate—Nausea—Docetaxel—ovarian cancer	0.000388	0.000936	CcSEcCtD
Alendronate—Dyspepsia—Epirubicin—ovarian cancer	0.000388	0.000936	CcSEcCtD
Alendronate—ATP6V1A—Disease—SMARCA4—ovarian cancer	0.000381	0.00327	CbGpPWpGaD
Alendronate—Pain—Epirubicin—ovarian cancer	0.000377	0.000909	CcSEcCtD
Alendronate—Constipation—Epirubicin—ovarian cancer	0.000377	0.000909	CcSEcCtD
Alendronate—ATP6V1A—Disease—EREG—ovarian cancer	0.000372	0.00319	CbGpPWpGaD
Alendronate—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000372	0.000896	CcSEcCtD
Alendronate—Feeling abnormal—Epirubicin—ovarian cancer	0.000363	0.000876	CcSEcCtD
Alendronate—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000361	0.000869	CcSEcCtD
Alendronate—Dyspepsia—Doxorubicin—ovarian cancer	0.000359	0.000866	CcSEcCtD
Alendronate—Urticaria—Epirubicin—ovarian cancer	0.00035	0.000844	CcSEcCtD
Alendronate—Constipation—Doxorubicin—ovarian cancer	0.000349	0.000841	CcSEcCtD
Alendronate—Pain—Doxorubicin—ovarian cancer	0.000349	0.000841	CcSEcCtD
Alendronate—Abdominal pain—Epirubicin—ovarian cancer	0.000349	0.00084	CcSEcCtD
Alendronate—Body temperature increased—Epirubicin—ovarian cancer	0.000349	0.00084	CcSEcCtD
Alendronate—Feeling abnormal—Doxorubicin—ovarian cancer	0.000336	0.000811	CcSEcCtD
Alendronate—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000334	0.000804	CcSEcCtD
Alendronate—ATP6V1A—Disease—FASN—ovarian cancer	0.000326	0.00279	CbGpPWpGaD
Alendronate—Hypersensitivity—Epirubicin—ovarian cancer	0.000325	0.000783	CcSEcCtD
Alendronate—ATP6V1A—Disease—PARP1—ovarian cancer	0.000324	0.00278	CbGpPWpGaD
Alendronate—Urticaria—Doxorubicin—ovarian cancer	0.000324	0.000781	CcSEcCtD
Alendronate—Abdominal pain—Doxorubicin—ovarian cancer	0.000323	0.000778	CcSEcCtD
Alendronate—Body temperature increased—Doxorubicin—ovarian cancer	0.000323	0.000778	CcSEcCtD
Alendronate—Asthenia—Epirubicin—ovarian cancer	0.000316	0.000763	CcSEcCtD
Alendronate—ATP6V1A—Signaling Pathways—HDAC6—ovarian cancer	0.000316	0.00271	CbGpPWpGaD
Alendronate—Pruritus—Epirubicin—ovarian cancer	0.000312	0.000752	CcSEcCtD
Alendronate—ATP6V1A—Disease—SLC2A1—ovarian cancer	0.000309	0.00265	CbGpPWpGaD
Alendronate—Diarrhoea—Epirubicin—ovarian cancer	0.000302	0.000727	CcSEcCtD
Alendronate—Hypersensitivity—Doxorubicin—ovarian cancer	0.000301	0.000725	CcSEcCtD
Alendronate—Asthenia—Doxorubicin—ovarian cancer	0.000293	0.000706	CcSEcCtD
Alendronate—Dizziness—Epirubicin—ovarian cancer	0.000292	0.000703	CcSEcCtD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	0.000291	0.00249	CbGpPWpGaD
Alendronate—Pruritus—Doxorubicin—ovarian cancer	0.000289	0.000696	CcSEcCtD
Alendronate—Vomiting—Epirubicin—ovarian cancer	0.00028	0.000676	CcSEcCtD
Alendronate—ATP6V1A—Signaling Pathways—YAP1—ovarian cancer	0.00028	0.0024	CbGpPWpGaD
Alendronate—Diarrhoea—Doxorubicin—ovarian cancer	0.000279	0.000673	CcSEcCtD
Alendronate—Rash—Epirubicin—ovarian cancer	0.000278	0.00067	CcSEcCtD
Alendronate—Dermatitis—Epirubicin—ovarian cancer	0.000278	0.00067	CcSEcCtD
Alendronate—Headache—Epirubicin—ovarian cancer	0.000276	0.000666	CcSEcCtD
Alendronate—ATP6V1A—Signaling Pathways—XIAP—ovarian cancer	0.000274	0.00235	CbGpPWpGaD
Alendronate—Dizziness—Doxorubicin—ovarian cancer	0.00027	0.00065	CcSEcCtD
Alendronate—FDPS—Metabolism—YAP1—ovarian cancer	0.000267	0.00229	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—SMARCA4—ovarian cancer	0.000267	0.00229	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	0.000265	0.00227	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PPP2R1A—ovarian cancer	0.000263	0.00226	CbGpPWpGaD
Alendronate—Nausea—Epirubicin—ovarian cancer	0.000262	0.000631	CcSEcCtD
Alendronate—ATP6V1A—Signaling Pathways—EREG—ovarian cancer	0.000261	0.00224	CbGpPWpGaD
Alendronate—Vomiting—Doxorubicin—ovarian cancer	0.000259	0.000625	CcSEcCtD
Alendronate—Rash—Doxorubicin—ovarian cancer	0.000257	0.00062	CcSEcCtD
Alendronate—Dermatitis—Doxorubicin—ovarian cancer	0.000257	0.00062	CcSEcCtD
Alendronate—Headache—Doxorubicin—ovarian cancer	0.000256	0.000616	CcSEcCtD
Alendronate—ATP6V1A—Signaling Pathways—PGR—ovarian cancer	0.000244	0.00209	CbGpPWpGaD
Alendronate—Nausea—Doxorubicin—ovarian cancer	0.000242	0.000584	CcSEcCtD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	0.000233	0.002	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PARP1—ovarian cancer	0.000227	0.00195	CbGpPWpGaD
Alendronate—FDPS—Metabolism—FASN—ovarian cancer	0.000218	0.00187	CbGpPWpGaD
Alendronate—FDPS—Metabolism—SLC5A5—ovarian cancer	0.000214	0.00184	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—TERT—ovarian cancer	0.000209	0.00179	CbGpPWpGaD
Alendronate—FDPS—Metabolism—SLC2A1—ovarian cancer	0.000207	0.00178	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	0.000203	0.00174	CbGpPWpGaD
Alendronate—FDPS—Metabolism—CYP1B1—ovarian cancer	0.000199	0.0017	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—CAV1—ovarian cancer	0.000193	0.00166	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PPP2R1A—ovarian cancer	0.000184	0.00158	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—IL6ST—ovarian cancer	0.000183	0.00157	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PPP2R1A—ovarian cancer	0.000176	0.00151	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—APC—ovarian cancer	0.000176	0.00151	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	0.000175	0.0015	CbGpPWpGaD
Alendronate—FDPS—Metabolism—ABCB1—ovarian cancer	0.000164	0.0014	CbGpPWpGaD
Alendronate—FDPS—Metabolism—TYMS—ovarian cancer	0.000161	0.00138	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PIK3CD—ovarian cancer	0.000155	0.00133	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—TERT—ovarian cancer	0.000146	0.00126	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—ERBB2—ovarian cancer	0.000137	0.00117	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CAV1—ovarian cancer	0.000135	0.00116	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PIK3CB—ovarian cancer	0.000135	0.00116	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—MTOR—ovarian cancer	0.000135	0.00116	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—ESR1—ovarian cancer	0.00013	0.00112	CbGpPWpGaD
Alendronate—FDPS—Metabolism—CAV1—ovarian cancer	0.000129	0.00111	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—IL6ST—ovarian cancer	0.000128	0.0011	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—CDKN1B—ovarian cancer	0.000127	0.00109	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	0.000124	0.00106	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—APC—ovarian cancer	0.000123	0.00106	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PIK3CG—ovarian cancer	0.000123	0.00106	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—CTNNB1—ovarian cancer	0.00012	0.00103	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PIK3CG—ovarian cancer	0.000118	0.00101	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PTEN—ovarian cancer	0.000117	0.001	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PIK3CD—ovarian cancer	0.000108	0.00093	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—STAT3—ovarian cancer	0.000104	0.000894	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—NRAS—ovarian cancer	0.000104	0.000892	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PIK3CD—ovarian cancer	0.000104	0.000889	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—MAPK3—ovarian cancer	9.96e-05	0.000854	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—MYC—ovarian cancer	9.69e-05	0.000831	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—ERBB2—ovarian cancer	9.57e-05	0.000821	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—MAPK1—ovarian cancer	9.48e-05	0.000813	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—EGFR—ovarian cancer	9.48e-05	0.000813	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—MTOR—ovarian cancer	9.45e-05	0.00081	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PIK3CB—ovarian cancer	9.45e-05	0.00081	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CXCL8—ovarian cancer	9.08e-05	0.000779	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PIK3CB—ovarian cancer	9.03e-05	0.000775	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—KRAS—ovarian cancer	8.95e-05	0.000768	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CDKN1B—ovarian cancer	8.87e-05	0.00076	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CASP3—ovarian cancer	8.69e-05	0.000745	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—IL2—ovarian cancer	8.68e-05	0.000744	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CCND1—ovarian cancer	8.46e-05	0.000725	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CTNNB1—ovarian cancer	8.38e-05	0.000718	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PIK3CA—ovarian cancer	8.22e-05	0.000705	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—MMP9—ovarian cancer	8.21e-05	0.000704	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PTEN—ovarian cancer	8.16e-05	0.0007	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PTEN—ovarian cancer	7.81e-05	0.000669	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—HRAS—ovarian cancer	7.61e-05	0.000653	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—VEGFA—ovarian cancer	7.37e-05	0.000632	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—STAT3—ovarian cancer	7.3e-05	0.000626	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—NRAS—ovarian cancer	7.28e-05	0.000625	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—IL6—ovarian cancer	7.28e-05	0.000625	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—MAPK3—ovarian cancer	6.98e-05	0.000598	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—MYC—ovarian cancer	6.78e-05	0.000582	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—AKT1—ovarian cancer	6.72e-05	0.000576	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—MAPK1—ovarian cancer	6.64e-05	0.000569	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—EGFR—ovarian cancer	6.64e-05	0.000569	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—KRAS—ovarian cancer	6.27e-05	0.000538	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PIK3CA—ovarian cancer	5.76e-05	0.000494	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—TP53—ovarian cancer	5.57e-05	0.000478	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PIK3CA—ovarian cancer	5.51e-05	0.000472	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—HRAS—ovarian cancer	5.33e-05	0.000457	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—IL6—ovarian cancer	5.1e-05	0.000437	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—AKT1—ovarian cancer	4.7e-05	0.000404	CbGpPWpGaD
Alendronate—FDPS—Metabolism—AKT1—ovarian cancer	4.5e-05	0.000386	CbGpPWpGaD
